Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 14:15:129-136.
doi: 10.2147/TCRM.S190641. eCollection 2019.

Experience of applying cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for ovarian teratoma with malignant transformation and peritoneal dissemination

Hsin-Hsien Yu  1   2 , Yutaka Yonemura  3   4 , Mao-Chih Hsieh  2   5 , Chang-Yun Lu  2 , Szu-Yuan Wu  6   7 , Yan-Shen Shan  1   8
Affiliations

Experience of applying cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for ovarian teratoma with malignant transformation and peritoneal dissemination

Hsin-Hsien Yu et al. Ther Clin Risk Manag. .

Abstract

Objectives: The prognosis of ovarian teratoma with malignant transformation and peritoneal dissemination (PD) is poor. This condition is rare but associated with a high recurrence rate even after aggressive debulking surgery and adjuvant chemotherapy. In the present paper, we describe our experience of using cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for this condition.

Methods: The data of ten female patients having ovarian teratoma with malignant transformation and PD between June 2007 and June 2017 were collected and reviewed retrospectively. CRS-HIPEC was performed according to the standard protocol. Patient characteristics, pathological reports, tumor markers, perioperative operative parameters, postoperative events, and disease status during the follow-up period were recorded.

Results: The primary ovarian neoplasms were pure mature cystic teratoma with malignant transformation (n=6, including 5 of mucinous adenocarcinoma), mixed germ cell tumor with mature cystic teratoma and yolk sac tumor (YST) (n=1), pure immature teratoma (n=1), immature teratoma with growing teratoma syndrome (GTS) (n=1), and immature teratoma mixed YST with GTS (n=1). The mean levels of tumor markers, including carcinoembryonic antigen, cancer antigen 19-9 (CA19-9), and CA125, were markedly elevated. The recurrence rate was 10%. The median and mean disease-free survival (DFS) after CRS-HIPEC were 22.3 and 36.2 months, respectively, and the 5-year DFS rate is 88%.

Conclusion: CRS-HIPEC is a safe therapeutic option for reducing the recurrence rate in selected patients with PD originating from ovarian teratoma with malignant transformation.

Keywords: cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; malignant transformation; ovarian teratoma; peritoneal dissemination.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Comparison of survival curve of HIPEC group vs non-HIPEC standard treatment group; The HIPEC group showed a higher 5-year DFS rate (88%) than the standard group (40%) (P=0.119). Abbreviations: HIPEC, hyperthermic intraperitoneal chemotherapy; DFS, disease-free survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Matz M, Coleman MP, Sant M, et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2) Gynecol Oncol. 2017;144(2):405–413. - PMC - PubMed
    1. Tavassoli FA, Devilee P, editors. WHO Classification of tumours Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 3rd ed. Lyon: IARC Press; 2003.
    1. Ghaemmaghami F, Hasanzadeh M, Karimi Zarchi M, Fallahi A. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study. Int J Surg. 2008;6(5):382–386. - PubMed
    1. Ueda G, Fujita M, Ogawa H, Sawada M, Inoue M, Tanizawa O. Adeno-carcinoma in a benign cystic teratoma of the ovary: report of a case with a long survival period. Gynecol Oncol. 1993;48(2):259–263. - PubMed
    1. McKenney JK, Soslow RA, Longacre TA. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol. 2008;32(5):645–655. - PubMed